홈 › 급성 골수성 백혈병 › 미네소타
미네소타의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 28개가 미네소타 내 여러 지역에서 참여자를 모집하고 있습니다.
미네소타의 도시
공식 연구 텍스트(영어)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 외 9개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Minnesota, Minneapolis
- HealthPartners Cancer Center at Regions Hospital (MN), Saint Paul
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 외 10개
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT05554406Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Sanford Joe Lueken Cancer Center, Bemidji
피험자 모집 중2상
60세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- 외 49개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Sanford Joe Lueken Cancer Center, Bemidji
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- 외 10개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT05564390CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Mayo Clinic Hospital - Rochester, Rochester
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05143996Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 외 9개
피험자 모집 중2상
18세 ~ 59세 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- 외 9개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06672146Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
- Mayo Clinic in Rochester, Rochester
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06279572A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
피험자 모집 중1상
21세 이하 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT07012044Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT07008638A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
피험자 모집 중3상
6 Months – 21 Years · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04293562Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Rochester MN-MAYOMN, Rochester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
피험자 모집 중1/2상
22세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04726241HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 14. 업데이트됨 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
피험자 모집 중2상
75세 이하 · 모든 성별 · 2026. 7. 6. 업데이트됨 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
피험자 모집 중2상
60세 이하 · 모든 성별 · 2026. 6. 25. 업데이트됨 · NCT03314974A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 10. 업데이트됨 · NCT03017820Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
- Mark Juckett, MD, Minneapolis
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 19. 업데이트됨 · NCT07591649MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
피험자 모집 중2상
2세 ~ 75세 · 모든 성별 · 2026. 4. 16. 업데이트됨 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 4. 13. 업데이트됨 · NCT05732103Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
- University of Minnesota/Masonic Cancer Center, Minneapolis
피험자 모집 중관찰 연구
25세 이하 · 모든 성별 · 2026. 4. 8. 업데이트됨 · NCT05014165MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- University of Minnesota Masonic Cancer Center, Minneapolis
피험자 모집 중2상
60세 이하 · 모든 성별 · 2026. 4. 6. 업데이트됨 · NCT05735717A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Minnesota, Minneapolis
- Mayo Clinic - Rochester, Rochester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 3. 13. 업데이트됨 · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Mayo Clinic, Rochester
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 2. 9. 업데이트됨 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Mayo Clinic, Rochester
피험자 모집 중건강한 지원자 환영
18세 ~ 120세 · 모든 성별 · 2025. 7. 25. 업데이트됨 · NCT05237258ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.